Gene: EPB41

2035
4.1R|EL1|HE
erythrocyte membrane protein band 4.1
protein-coding
1p35.3
Ensembl:ENSG00000159023 MIM:130500 Vega:OTTHUMG00000003644 UniprotKB:P11171
NG_013344.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.027e-1 (AD)  5.859e-2 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ATXN70.821
UBR50.809
MLLT100.808
TNXB0.804
ZNF5500.796
GGA20.79
UBR40.789
TRRAP0.786
SETD50.785
CCDC930.783

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.347
OR4F29-0.323
BCL7C-0.303
KLRC3-0.299
FXYD4-0.291
CTNNA3-0.29
KLRC2-0.284
TSPAN8-0.283
PAQR6-0.282
C5orf64-0.279

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4728291-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole"1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole results in increased expression of EPB41 mRNA"27071940
C4728291-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole"NFE2L2 gene mutant form inhibits the reaction [1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole results in increased expression of EPB41 mRNA]"27071940
C0284513,4,3',4'-tetrachlorobiphenyl"3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of EPB41 mRNA]"19467301
C0293704-toluidine4-toluidine results in increased expression of EPB41 mRNA27638505
D000082AcetaminophenAcetaminophen results in decreased expression of EPB41 mRNA21420995|2223033
D000111Acetylcysteine[Acetylcysteine co-treated with Atorvastatin Calcium] inhibits the reaction [sodium arsenite results in decreased expression of EPB41 protein]20946910
C430898AGN 194204AGN 194204 results in decreased expression of EPB41 mRNA16339527
D000393Air PollutantsAir Pollutants analog results in decreased expression of EPB41 mRNA21757418
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of EPB41 mRNA21298039
D001151ArsenicArsenic affects the methylation of EPB41 gene25304211
D000069059Atorvastatin Calcium[Acetylcysteine co-treated with Atorvastatin Calcium] inhibits the reaction [sodium arsenite results in decreased expression of EPB41 protein]20946910
D001280AtrazineAtrazine results in decreased expression of EPB41 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of EPB41 mRNA22323515
C030935benz(a)anthracenebenz(a)anthracene results in decreased expression of EPB41 mRNA26377693
C030935benz(a)anthracene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA27858113
C006703benzo(b)fluoranthene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA27858113
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in decreased expression of EPB41 mRNA26377693
D001564Benzo(a)pyrene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA27858113
C110772benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketonebenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]20946910
C110772benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketonebenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein]20946910
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in decreased expression of EPB41 mRNA25270620
C006780bisphenol Abisphenol A results in increased expression of EPB41 mRNA27685785
C006780bisphenol Abisphenol A affects the methylation of EPB41 promoter27334623
C006780bisphenol Abisphenol A results in decreased methylation of EPB41 promoter27312807
C006780bisphenol Abisphenol A results in increased expression of EPB41 mRNA25181051
C018475butyraldehydebutyraldehyde results in decreased expression of EPB41 mRNA26079696
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of EPB41 mRNA23650126
D002737ChloropreneChloroprene results in increased expression of EPB41 mRNA23125180
D002784Cholesterolbenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]20946910
D002784Cholesterolbenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein]20946910
D002784Cholesterol[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein20946910
D002784Cholesterol[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein20946910
C074702chromium hexavalent ionchromium hexavalent ion results in decreased expression of EPB41 mRNA27793765
C031180chrysene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EPB41 mRNA27858113
C031180chrysenechrysene results in decreased expression of EPB41 mRNA26377693
D002922CiguatoxinsCiguatoxins affects the expression of EPB41 mRNA18353800
D002994ClofibrateClofibrate results in decreased expression of EPB41 mRNA17585979
C018021cobaltous chloridecobaltous chloride results in increased expression of EPB41 mRNA24386269
D016572CyclosporineCyclosporine results in increased expression of EPB41 mRNA20106945|2798913
C014347decitabinedecitabine affects the expression of EPB41 mRNA17145863
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of EPB41 mRNA21266533
D004041Dietary Fats"3,4,3',4'-tetrachlorobiphenyl inhibits the reaction [Dietary Fats results in increased expression of EPB41 mRNA]"19467301
D004041Dietary FatsDietary Fats results in increased expression of EPB41 mRNA19467301
D004052Diethylnitrosamine[Piperonyl Butoxide co-treated with Diethylnitrosamine] affects the methylation of EPB41 gene23968726
C042080diisodecyl phthalatediisodecyl phthalate results in decreased expression of EPB41 mRNA25270620
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of EPB41 mRNA23300682
D005485FlutamideFlutamide results in increased expression of EPB41 mRNA24136188
D019833GenisteinGenistein results in increased expression of EPB41 mRNA21048042
D006861Hydrogen Peroxidebenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]20946910
D006861Hydrogen Peroxidebenzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein]20946910
D006861Hydrogen Peroxide[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein20946910
D006861Hydrogen Peroxide[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein20946910
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of EPB41 mRNA25613284
D007854LeadLead affects the expression of EPB41 mRNA28903495
D007854LeadLead affects the splicing of EPB41 mRNA28903495
C523799MRK 003EPB41 results in decreased susceptibility to MRK 00319903844
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of EPB41 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of EPB41 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of EPB41 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of EPB41 mRNA"25620056
C017096n-butoxyethanoln-butoxyethanol results in increased expression of EPB41 mRNA19812364
C051752nefazodonenefazodone results in increased expression of EPB41 mRNA24136188
C012655nimesulidenimesulide results in increased expression of EPB41 mRNA24136188
C016030pantogabpantogab results in increased expression of EPB41 mRNA17379144
D010634PhenobarbitalPhenobarbital affects the expression of EPB41 mRNA23091169
D010634PhenobarbitalPhenobarbital results in increased expression of EPB41 mRNA19162173
D010882Piperonyl Butoxide[Piperonyl Butoxide co-treated with Diethylnitrosamine] affects the methylation of EPB41 gene23968726
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of EPB41 mRNA19710929
C006253pirinixic acidpirinixic acid results in increased expression of EPB41 mRNA18301758|1844570
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of EPB41 mRNA22714537
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in increased expression of EPB41 mRNA28903501
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in increased expression of EPB41 mRNA19162173
C009277sodium arsenatesodium arsenate results in increased expression of EPB41 mRNA16882884
C009277sodium arsenatesodium arsenate results in increased expression of EPB41 mRNA21795629
C017947sodium arsenitesodium arsenite affects the methylation of EPB41 gene28589171
C017947sodium arsenite[Acetylcysteine co-treated with Atorvastatin Calcium] inhibits the reaction [sodium arsenite results in decreased expression of EPB41 protein]20946910
C017947sodium arsenitesodium arsenite results in decreased expression of EPB41 protein20946910
D012999SomanSoman results in increased expression of EPB41 mRNA19281266
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EPB41 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of EPB41 mRNA21215274
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of EPB41 mRNA25613284
D019772TopotecanTopotecan results in decreased expression of EPB41 mRNA25729387
C012589trichostatin Atrichostatin A results in increased expression of EPB41 mRNA28542535
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of EPB41 mRNA19042947
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of EPB41 mRNA"26179874
C057693troglitazonetroglitazone results in decreased expression of EPB41 mRNA28973697
D014635Valproic AcidValproic Acid affects the expression of EPB41 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of EPB41 mRNA23179753|2352703
D014635Valproic AcidValproic Acid results in increased methylation of EPB41 gene29154799
D014635Valproic AcidValproic Acid affects the expression of EPB41 mRNA17292431|1796380
D014638VanadatesVanadates results in decreased expression of EPB41 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of EPB41 gene25560391
C111237vorinostatvorinostat results in decreased expression of EPB41 mRNA27188386

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003779actin binding-IEA-  
GO:0005200structural constituent of cytoskeleton-TAS6894932  
GO:0005515protein binding-IPI8922391  10692436  11003675  16060676  16254212  16669616  
20109190  23870127  24996901  
GO:0005516calmodulin binding-IEA-  
GO:00055451-phosphatidylinositol binding-IDA16669616  
GO:0008022protein C-terminus binding-IMP20109190  
GO:0030507spectrin binding-TAS3693401  
GO:0047485protein N-terminus binding-IMP20109190  
GO:0051219phosphoprotein binding-IMP20109190  
GO ID GO Term Qualifier Evidence PubMed
GO:0007049cell cycle-IEA-  
GO:0008360regulation of cell shape-IMP6894932  
GO:0030036actin cytoskeleton organization-NAS8434260  
GO:0030866cortical actin cytoskeleton organization-IEA-  
GO:0031032actomyosin structure organization-IBA21873635  
GO:0032092positive regulation of protein binding-IDA3693401  
GO:0051301cell division-IEA-  
GO:0065003protein-containing complex assembly-IEA-  
GO:1904778positive regulation of protein localization to cell cortex-IMP23870127  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IEA-  
GO:0005829cytosol-IDA-  
GO:0005829cytosol-TAS-  
GO:0005856cytoskeleton-IBA21873635  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membrane-IDA-  
GO:0005886plasma membrane-IMP6894932  
GO:0009898cytoplasmic side of plasma membrane-IEA-  
GO:0014069postsynaptic density-IEA-  
GO:0014731spectrin-associated cytoskeleton-TAS3693401  
GO:0030054cell junction-IDA-  
GO:0030863cortical cytoskeleton-IDA16254212  
GO:0032991protein-containing complex-IDA16060676  
GO:0032991protein-containing complex-IMP20109190  
GO:0099738cell cortex region-IDA23870127  
KEGG ID KEGG Term
hsa04530Tight junction
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-6794361Neurexins and neuroliginsTAS
R-HSA-6794362Protein-protein interactions at synapsesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
21808284Gender-stratified gene and gene-treatment interactions in smoking cessation. (2012 Dec)Lee WPharmacogenomics J